"GLP-1 is not a foreign molecule. It is a hormone your intestines release after every meal, a chemical signal between your gut and your brain that says Slow down, you've had enough. The drugs don't introduce something new to the body—they connect with receptors that are already there."
"Between 40 and 70 percent of patients on these drugs report gastrointestinal adverse effects, like acid reflux, chronic diarrhea, and/or constipation. Studies now show that patients on GLP-1 agonists face a nearly fourfold increased risk of gastroparesis and a ninefold increased risk of pancreatitis compared to people on other weight-loss medications."
GLP-1 receptor agonists, such as Ozempic and Wegovy, are widely used for obesity and diabetes treatment. These drugs enhance the natural hormone GLP-1, signaling fullness. However, concerns arise about the effects of excessive stimulation of this pathway. Many patients report gastrointestinal issues, with studies indicating a higher risk of conditions like gastroparesis and pancreatitis. The long-term consequences of flooding the body with pharmacological doses of GLP-1 remain uncertain, raising questions about the safety of these medications.
Read at Slate Magazine
Unable to calculate read time
Collection
[
|
...
]